{"id":"NCT01922102","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","officialTitle":"A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-11","primaryCompletion":"2016-09-14","completion":"2016-09-14","firstPosted":"2013-08-14","resultsPosted":"2019-06-24","lastUpdate":"2019-06-24"},"enrollment":457,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)"],"interventions":[{"type":"DRUG","name":"Ranibizumab 0.5mg","otherNames":["Lucentis"]},{"type":"DRUG","name":"Ranibizumab 0.5 mg","otherNames":["Lucentis"]},{"type":"DRUG","name":"Verteporfin PDT","otherNames":["Visudyne"]}],"arms":[{"label":"Group I","type":"EXPERIMENTAL"},{"label":"Group II","type":"EXPERIMENTAL"},{"label":"Group III","type":"ACTIVE_COMPARATOR"}],"summary":"This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)","primaryOutcome":{"measure":"Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3","timeFrame":"From Baseline to Month 3","effectByArm":[{"arm":"Group I","deltaMin":53.7,"sd":12.65},{"arm":"Group II","deltaMin":54.2,"sd":13.01},{"arm":"Group III","deltaMin":52.6,"sd":12.29}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":47,"countries":["China","Hong Kong","India","Philippines","South Korea","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":182},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Conjunctival haemorrhage (Study eye)","Cough","Xerophthalmia (Study eye)"]}}